Showing Results for
From:Future Oncology (Vol. 11, Issue 11s) Peer-ReviewedAuthor(s): Peter Reichardt [*] Trabectedin has mechanisms of action that differentiate it from conventional cytotoxic agents used in the treatment of advanced soft tissue sarcoma; the possibility that these multiple...
From:Future Oncology (Vol. 11, Issue 11s) Peer-ReviewedAuthor(s): Giovanni Grignani aff1 , Javier Martín-Broto aff2 , Markus Schuler aff3 , Peter Reichardt [*] aff4 KEYWORDS clinical case studies; dosing guidelines; neoadjuvant chemotherapy; synovial sarcoma;...
From:Future Oncology (Vol. 11, Issue 11s) Peer-ReviewedAuthor(s): Axel Le Cesne [*] aff1 , Peter Reichardt aff2 KEYWORDS advanced soft tissue sarcoma; elderly patients; maintenance treatment; safety; trabectedin; treatment optimization Trabectedin is indicated for...
Choose how you want to be alerted when new results for your search become available.
Subscribe to Gale's RSS feed to get content delivered to your favorite RSS aggregator. Copy and paste the URL below into your reader:
Tell us where to send the alert and how often you want to receive it